COMP <GO>
TRLV vs MRK // RSI-14 & 200D SMA MOMENTUM
Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: TRLV 2
— MRK 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MRK
LAST: $10.60 (-0.19%) • MKT CAP: $2.04B
rsi-technicals
48.3
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
rsi-technicals
51.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRLV VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRLV | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.20% | 74.80% | -14.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 20.70% | -7.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.9x | 15.3x | -5.40 | TRLV | /valuation <GO> |
| Free Cash Flow Yield | 11.20% | 3.42% | +7.78 | TRLV | /fcf-yield <GO> |
| Operating Margin | 12.10% | 34.30% | -22.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | -9.90% | 28.10% | -38.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -0.40% | 1.30% | -1.70 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.12 | 5.19 | -4.07 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 48.3 | 51.7 | -3.40 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.04B | $361.02B | -$358.98B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRLV REV | MRK REV | TRLV GROSS % | MRK GROSS % | TRLV FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.18B | $65.01B | 60.2% | 74.8% | $228.6M | $12.36B |
| FY 2024 | $1.19B | $64.17B | 60.3% | 76.3% | $148.9M | $18.10B |
| FY 2023 | $1.13B | $60.12B | — | — | $201.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRLV // BETA —
MRK // BETA 0.92